Fundraising FoxBond Biosciences
Parkville, US · Founded 2015 · Delaware corporation · 2 known investors
Find your way into Bond Biosciences
Sign up to see every warm intro you have to Bond Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bond Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Bond Biosciences is a clinical-stage biopharmaceutical company developing non-absorbed oral therapeutics that bind excess ions in the gastrointestinal tract to treat ion-related diseases. Its lead candidate, BBI-001, is designed to inhibit dietary iron absorption for patients with iron overload from Hereditary Hemochromatosis.
Founders & leadership
MA
Michael A. RileyExecutive
CB
Cory BerklandNamed on SEC filing
Board
MB
Michael BeckloffBoard director
TO
Timothy OplerBoard director
Investors · 2
Also in the syndicate · 1
Collage Partnerslead
Reported raises · per SEC filings
Form D private placements$24.1M disclosed across 5 rounds · 2020–2026
▶$7.6MraisedOct 2026 · 122 investors · Other Health CareRule 506(b)
▶$7.6MraisedOct 2026 · 122 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Michael BeckloffDirector
- Cory BerklandExecutive Officer, Director
- Timothy OplerDirector
- Michael A. RileyExecutive Officer, Director
- Jay ShepardDirector
- Offering amount
- $15M
- Amount sold
- $7.6M
- Sales commissions
- $528.7K
- Placement agents
- Stonehaven, LLC
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.5MraisedJan 2026 · 91 investors · Other Health CareRule 506(b)
▶$4.5MraisedJan 2026 · 91 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Michael BeckloffDirector
- Timothy OplerDirector
- Cory BerklandExecutive Officer, Director
- Michael A. RileyExecutive Officer, Director
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- Sales commissions
- $315.8K
- Placement agents
- Stonehaven, LLC
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.8MraisedJan 2022 · 81 investors · Other Health CareRule 506(b)
▶$6.8MraisedJan 2022 · 81 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Michael BeckloffDirector
- Cory BerklandExecutive Officer, Director
- Timothy OplerDirector
- Michael A. RileyExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $6.8M
- Minimum investment
- $1
- Sales commissions
- $408.6K
- Proceeds to insiders
- $585.8K
- Placement agents
- Stonehaven, LLC
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedDec 2020 · 57 investors · Other Health CareRule 506(b)
▶$5MraisedDec 2020 · 57 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Michael A. RileyExecutive Officer, Director
- Cory BerklandExecutive Officer, Director
- Timothy OplerDirector
- Offering amount
- $6M
- Amount sold
- $5M
- Minimum investment
- $1
- Sales commissions
- $350K
- Proceeds to insiders
- $273K
- Placement agents
- CIM Securities, LLC
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$200KraisedSep 2020 · 8 investors · Other Health CareRule 506(b)
▶$200KraisedSep 2020 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Cory BerklandDirector
- Timothy OplerDirector
- Michael A. RileyExecutive Officer, Director
- Offering amount
- $200K
- Amount sold
- $200K
- Sales commissions
- $14K
- Placement agents
- CIM Securities, LLC
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Bond Biosciences do?
- Bond Biosciences is a clinical-stage biopharmaceutical company developing non-absorbed oral therapeutics that bind excess ions in the gastrointestinal tract to treat ion-related diseases. Its lead candidate, BBI-001, is designed to inhibit dietary iron absorption for patients with iron overload from Hereditary Hemochromatosis.
- Who are Bond Biosciences's investors?
- Bond Biosciences's investors include BioGenerator Ventures.
- How much funding has Bond Biosciences raised?
- Bond Biosciences has disclosed $24.1M raised across 5 rounds.
- Where is Bond Biosciences headquartered?
- Bond Biosciences is headquartered in Parkville, US.